Tablets, film-coated pale green color, oval, biconcave, with dividing Valium.
New Pass dry extract (obtained from the rhizomes and roots of valerian, lemon balm herb, St. John's wort grass, leaves and flowers of Crataegus monogyna or prickly, herbs passionflower inkarnatnoy (passion), stems of hop ordinary, flowers elderberry), 157.5 mg
200 mg guaifenesin
Inactive ingredients: colloidal silicon dioxide, microcrystalline cellulose, glycerol, magnesium stearate, lactose monohydrate.
Cover structure: Opadry "AMB 80W31115" Green (polyvinyl alcohol, titanium dioxide, talc, soya lecithin, xanthan gum, dye quinoline yellow, iron oxide yellow, indigo carmine dye).
From the digestive system: rarely - nausea, vomiting, cramps, heartburn, diarrhea, constipation.
CNS: rarely - decreased concentration, dizziness, drowsiness.
Other: rarely - allergic reactions, rash, fatigue, mild muscle weakness. The symptoms quickly disappear after discontinuation of the drug.
The patient should be warned that the appearance of these or other side effects should consult a doctor.
During treatment with Novo Passit® should not drink alcohol.
With care use in patients with acute diseases of the gastrointestinal tract.
The patient should be warned that if within 7 days of therapy, the symptoms do not disappear or they will gain, it is recommended to consult a doctor.
During the reception, the New Passit® drug should avoid exposure to ultraviolet radiation (long-term exposure to direct sunlight, solarium), especially in patients with fair skin.
The drug in the form of a solution is not recommended for use in patients with impaired glucose uptake and galactose and congenital fructose intolerance.
Patients with diabetes should be borne in mind that 100 g of a solution for oral administration contains 12.5-14.2 13.6-15.3 g g glucose and fructose. When taken in recommended doses, each dose containing not more than 1.42 g of glucose and 1.53 g fructose.
Oral solution contains 12.19% ethanol; Each single dose contains up to 0,481 g of ethanol.
Effects on ability to drive vehicles and management mechanisms
In the period of treatment should refrain from activities potentially hazardous activities that require high concentration and psychomotor speed reactions. Do not drive vehicles and mechanis
- Neurasthenia and neurotic reactions, accompanied by irritability, anxiety, fear, fatigue, distraction;
- "Manager syndrome" (a state of constant mental stress);
- Insomnia (mild forms);
- Headaches caused by nervous tension;
- Functional gastrointestinal diseases (dyspeptic syndrome, irritable bowel syndrome);
- As a symptomatic agent in neuro dystonia and menopausal syndrome;
- Pruritic dermatoses (atopic and seborrheic dermatitis, urticaria), caused by psychological stress.
- Myasthenia gravis;
- Children up to age 12 years;
- Hypersensitivity to the drug.
Precautions should use the drug in patients with acute gastrointestinal diseases, liver diseases, alcoholism, diseases and injuries of the brain in epilepsy.